ALGAE CALCIUM VEGCAL™ Pharma Grade API is a marine calcareous algae-derived calcium carbonate active pharmaceutical ingredient supplied for oral tablet, capsule, granule, and injectable dosage forms. The model designation covers milled and unmilled grades; milled grades are controlled for particle size distribution, bulk density, tapped density, and specific surface area to support direct compression and capsule filling, while unmilled grades may be specified for dry granulation or specialized suspension processing. Identity is confirmed by reaction with 6 M acetic acid, followed by precipitation with ammonium oxalate, as described in the European Pharmacopoeia calcium carbonate monograph and the corresponding United States Pharmacopeia Calcium Carbonate monograph. The API is not a synthetic precipitated calcium carbonate; it retains the porous algal skeletal structure, with calcite and aragonite fractions that vary by harvest lot. Elemental calcium content is typically 34–38% w/w on the dried substance, with residual magnesium, strontium, and silica present at trace concentrations. The material should be qualified against the specific dosage form because residual magnesium and strontium influence tablet hardness and acid neutralization kinetics in ways not predicted by pure calcium carbonate compendial standards.

Manufacturing is performed under ICH Q7 current good manufacturing practice for active pharmaceutical ingredients. Batch release includes infrared absorption spectrophotometry per Ph.Eur. 2.2.24 and carbonate assay by gasometric measurement. The natural marine origin requires additional control of acid-insoluble siliceous matter and residual organic debris; acceptance criteria are established per lot-specific certificate of analysis.

What limits direct compression of high-dose algae calcium in tablet tooling configurations?

Direct compression of high-dose calcium formulations is governed by the compressibility of the porous algal particles and the flow function coefficient of the powder blend. Bulk densities in the range 0.55–0.85 g/cm³ create high tablet weight variability when final tablet mass exceeds 1,500 mg. On rotary tablet presses, the powder must pass through a paddle feeder at turret speeds above 40 rpm; if the flow function coefficient falls below 4, bridging in the feed frame and weight coefficient of variation above 2% are commonly observed. The porous structure collapses at compaction pressures above 150 MPa, causing loss of porosity and reduced disintegration velocity. At compaction pressures below 80 MPa, tensile strength may be insufficient for film coating, and lamination at the tablet band can occur due to elastic recovery of the algal skeletal fragments. Tooling with deep concave or shallow concave configurations may require reduced turret speed and extended dwell time. Forced feeding systems are mandatory; gravity-fed machines produce inconsistent fill. Pre-compression force of 10–30 kN and main compression force of 20–60 kN are typical for a 10 mm round tool on a high-speed rotary press.

Lubricant selection and concentration are critical. Magnesium stearate at 0.5–1.0% w/w is sufficient for ejection; above 1.0% w/w, hydrophobic film formation can extend disintegration time beyond 15 minutes when tested according to USP 701. Below 0.5% w/w, ejection force can rise above 2 kN, causing punch scoring and tablet capping. The compressibility factor and Hausner ratio are determined per USP 1174; a Hausner ratio above 1.35 indicates cohesive flow and requires glidant addition. Fumed silica at 0.1–0.5% w/w may reduce interparticle friction but may reduce tablet tensile strength if over-blended. Magnesium stearate blending time should not exceed 5 minutes at 25 rpm in a bin blender; longer blending can produce over-lubrication. The high surface area of the milled grade also requires pre-drying at relative humidity above 60% because adsorbed moisture alters flow and causes picking on punch tips. A moisture specification of ≤2% loss on drying is recommended before direct compression. Over-drying below 1.5% can increase static charge and dust.

Wet granulation using aqueous binders should be conducted at pH values above 6.0 to avoid excessive carbon dioxide release from the carbonate matrix; acidic granulation media below pH 5.5 cause foaming and can reduce calcium assay by localized dissolution. Roller compaction is often preferred for high-dose oral formulations because it preserves particle porosity better than slugging. A roller pressure of 40–80 kN/cm and gap setting of 1.5–3.0 mm produce ribbons that, after milling, yield granules with a d50 of 180–350 µm. Ribbon density between 1.2–1.6 g/cm³ is typical; lower density ribbons produce excessive fines. Granules should be dried to loss on drying ≤2% before compression; residual moisture above 3% can increase punch sticking. Fluid-bed granulation using top spray with binder solution at spray rate 20–50 g/min and inlet air temperature 60–75°C can produce granules with acceptable compactibility, but the carbonate may react with acidic binders. A hydroxypropyl methylcellulose 5% w/w binder solution yields granules with friability below 1% in development-scale trials. Capsule filling on dosator-type machines requires tapped density above 0.80 g/cm³; otherwise, plug ejection causes weight variation. For tamping disc machines, a blend with Carr index below 25 is recommended to maintain fill control. Empty gelatin capsules filled with algae calcium should be stored below 40% relative humidity to prevent shell embrittlement. For a target fill weight of 600–800 mg in size 00 capsules, the powder bed must be pre-compressed by tamping pins to a plug density above 1.0 g/cm³.

Dissolution, acid neutralization, and calcium bioavailability comparisons

The porous algal structure influences dissolution and acid neutralization relative to other calcium salts. The material’s acid neutralization capacity is derived from carbonate content; the reaction with hydrochloric acid follows the stoichiometry of calcium carbonate. Pure calcium carbonate has a theoretical acid neutralization capacity of 20 mEq/g; the value for algal material may be lower due to non-carbonate minerals. In vitro dissolution, if required, is tested in 0.1 M hydrochloric acid at 37±0.5°C using USP 711 apparatus II. The high specific surface area may accelerate gastric pH buffering compared with ground limestone calcium carbonate of equivalent particle size, but the magnitude depends on the calcite/aragonite ratio and the accessible pore volume. Published comparative bioavailability data for algal calcium carbonate remain limited; compendial calcium carbonate monographs do not require dissolution testing. In vivo equivalence for modified-release or chewed presentations should be established by crossover pharmacokinetic studies rather than inferred from acid neutralization alone.

When injectable-grade algae calcium is specified for parenteral delivery

Direct intravenous injection of calcium carbonate is limited by low aqueous solubility; the solubility product Ksp of calcite is approximately 3.36×10⁻⁹ at 25°C, yielding an intrinsic solubility near 13 mg/L in pure water. Injectable presentations are therefore typically formulated as sterile suspensions or used as an intermediate for conversion to a soluble calcium salt. Dedicated injectable grades must meet USP 85 endotoxin limits derived from the maximum intended dose; for gram-scale calcium doses, endotoxin specifications below 0.25 EU/mg are common. Particulate matter in injectable suspensions is controlled per USP 788; the final suspension must meet ≤6,000 particles per container ≥10 µm and ≤600 particles per container ≥25 µm under the light obscuration test, unless the monograph specifies the microscopic method.

Sterilization by moist heat at 121°C for 15 minutes may alter particle size distribution; terminal sterilization of algal calcium suspensions requires stability verification of zeta potential and sedimentation volume. The algal particle surface zeta potential in water for injection may be near -20 mV to -30 mV at pH 7.0, depending on residual organic matter; this is usually insufficient for electrostatic stabilization, so nonionic surfactants or wetting agents at low concentration may be required. Sterile filtration is not applicable to suspensions; terminal sterilization by moist heat or aseptic compounding are the only practical routes. Aseptic processing is required if terminal sterilization cannot be validated. Elemental impurities for the parenteral route are controlled under ICH Q3D with limits typically lower than oral grades, and analysis is carried out by ICP-MS per USP 233. Aluminum, cadmium, lead, arsenic, and mercury are of particular concern because marine carbonate sources can concentrate these elements; parenteral aluminum is evaluated against the ICH Q3D permitted daily exposure. A typical release limit is ≤1 µg/g for aluminum, but the acceptable value must be derived from the maximum daily dose. Compatibility with common parenteral buffers is limited: phosphate buffers can precipitate calcium phosphate, and sulfate-containing diluents can precipitate calcium sulfate. The algal skeletal particles may require micronization to d90 below 10 µm for suspension stability; wet media milling with zirconia beads 0.3–0.5 mm is one processing route. If a soluble calcium salt is intended, the algae calcium carbonate can be converted to calcium chloride or calcium gluconate by reaction with pharmaceutical grade acid; this conversion must be performed under controlled pH to avoid residual carbonate.

Moisture protection is required because the porous structure adsorbs up to 2–4% w/w water at relative humidity above 60%. The API should be stored in closed containers at 15–25°C and protected from acid vapors. Stability studies under ICH Q1A(R2) include long-term 25°C/60% RH and accelerated 40°C/75% RH conditions. At higher humidity, the porous material can form surface hydrates and increase moisture content by 1–2% within 48 hours. Containers should include desiccant if the closure has moisture vapor transmission rate above 0.5 g/m²/day. Packaging in double polyethylene liners inside fiber drums of 25 kg or 50 kg net weight is typical. In oral manufacturing suites, containment is not required beyond standard pharmaceutical dust controls; however, blending with acidic excipients such as citric acid monohydrate should be avoided in damp granulation because premature reaction generates carbon dioxide and can compromise granule integrity. The milled grade is compatible with dry blending, roller compaction, and capsule filling; for wet granulation, the granulating fluid should be water or an aqueous binder at neutral to slightly alkaline pH. Retest dating is assigned from real-time stability data under ICH Q1A conditions for the intended market.